Vertex Pharmaceuticals dropped an mRNA-based cystic fibrosis therapy, citing delivery and tolerability challenges that the company says resemble issues seen in other parts of the gene-medicine field. The Boston-based company said it discontinued development after confronting limitations in delivering the genetic medicine. Separately, Vertex also ended its inhaled cystic fibrosis program partnered with Moderna after an earlier trial pause for subpar tolerability. Together, the actions show Vertex narrowing its CF portfolio in the face of constraints that have repeatedly slowed inhaled and genetic delivery approaches. For investors and partners, the departures highlight a key gating item for platform bets: patient tolerability and delivery practicality, not just biological rationale and molecular design.